A Multi Center, Non-randomized, Open, Phase 3 Study to Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis in Prostate Cancer Risk Groups
Latest Information Update: 31 Oct 2023
Price :
$35 *
At a glance
- Drugs F-18 Florastamin (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Registrational
- Sponsors FutureChem
- 26 Oct 2023 Planned End Date changed from 31 May 2022 to 1 Jul 2024.
- 26 Oct 2023 Planned primary completion date changed from 31 May 2022 to 1 Jul 2024.
- 26 Oct 2023 Status changed to recruiting.